Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma

References

• Lipinski KA, Barber LJ, Davies MN, et al. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer. 2016;2:49–63.
   PubMed Web of Science ®Google Scholar
• Yuppa DP. The emperor of all Maladies: a biography of cancer. Psychooncology. 2012;21:e7–e8.
   Web of Science ®Google Scholar
• Park YN, Kim YB, Yang KM, et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med. 2000;124:1061–1065.
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.
   PubMed Web of Science ®Google Scholar
• Jang HJ, Lee SA, Seong S, et al. Combined treatment for lung metastasis from hepatocellular carcinoma: a case report. Explore. 2018;14:385-388.
   Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Yao Y, Su Z, Liang Y. et al. pH-sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int J Nanomed. 2015;10:6185–6197.
   PubMed Web of Science ®Google Scholar
• Guan JB, Sun J, Sun FL, et al. Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes. Nanoscale. 2017;9:9190–9201.
   PubMed Web of Science ®Google Scholar
• Wang TQ, Yu XY, Han LQ, et al. Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA. Int J Nanomed. 2017;12:4773–4788.
   PubMed Web of Science ®Google Scholar
• Moller K, Muller K, Engelke H, et al. Highly efficient siRNA delivery from core-shell mesoporous silica nanoparticles with multifunctional polymer caps. Nanoscale. 2016;8:4007–4019.
   PubMed Web of Science ®Google Scholar
• Duan XM, Mu MJ, Yan JF, et al. Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy. IJN. 2018;13:1443–1456.
   Web of Science ®Google Scholar
• Tsouris V, Joo MK, Kim SH, et al. Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. Biotechnol Adv. 2014;32:1037–1050.
   PubMed Web of Science ®Google Scholar
• Kanamala M, Wilson WR, Yang M, et al. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152–167.
   PubMed Web of Science ®Google Scholar
• Dong D, Gao W, Liu Y, et al. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Lett. 2015;359:178–186.
   PubMed Web of Science ®Google Scholar
• Ju C, Mo R, Xue J, et al. Sequential intra-intercellular nanoparticle delivery system for deep tumor penetration. Angew Chem Int Ed. 2014;53:6253–6258.
   PubMed Web of Science ®Google Scholar
• Lin Q, Chen J, Zhang Z, et al. Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine. 2014;9:105–120.
   PubMed Web of Science ®Google Scholar
• Ma D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale. 2014;6:6415–6425.
   PubMed Web of Science ®Google Scholar
• Du Z, Munye MM, Tagalakis AD, et al. The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations. Sci Rep. 2014;4:7107.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gao H, He J, et al. Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: a dual cell therapy to regress plaques. J Control Release. 2018;283:241–260.
   PubMed Web of Science ®Google Scholar
• Shen J, Sun H, Meng Q, et al. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA. Mol Pharm. 2014;11:3342–3351.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Li JQ, Wang ZZ, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35:5226–5239.
   PubMed Web of Science ®Google Scholar
• Stapleton S, Jaffray D, Milosevic M. Radiation effects on the tumor microenvironment: implications for nanomedicine delivery. Adv Drug Deliv Rev. 2017;109:119–130.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Malhotra M, Curtin CM, et al. Life in 3D is never flat: 3D models to optimise drug delivery. J Control Release. 2015;215:39–54.
   PubMed Web of Science ®Google Scholar
• Wientjes MG, Yeung BZ, Lu Z, et al. Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids. J Control Release. 2014;192:10–18.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li M, Chen B, et al. Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids. AAPS J. 2013;15:816–831.
   PubMed Web of Science ®Google Scholar
• Ge YL, Zhang X, Zhang JY, et al. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol. 2009;9:389–395.
   PubMed Web of Science ®Google Scholar
• Miao RC, Xu XS, Wang ZX, et al. Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway. Mol Med Rep. 2018;17:3735–3743.
   PubMed Web of Science ®Google Scholar